Does the Use of Erythropoietin Reduce the Risk of Exposure to Allogeneic Blood Transfusion in Cardiac Surgery? A Systematic Review and Meta‐Analysis

Abstract  Background: The use of blood conservation techniques is important in cardiac surgery as postoperative bleeding is common and allogeneic blood transfusion carries the risk of transfusion reactions and infection transmission. Erythropoietin with and without preoperative autologous blood donation is one of the modalities to avoid allogeneic blood transfusion. The objective of this review was to assess the effectiveness of erythropoietin in reducing the risk of exposure to allogeneic blood transfusion during or after cardiac surgery. Methods: A meta‐analysis of 11 identified randomized controlled trials, reporting comparisons between erythropoietin and control, was undertaken. The primary outcome was the number of patients exposed to allogeneic blood transfusion during or after cardiac surgery. Results: Eleven studies, involving 708 patients, met the inclusion criteria for this review. In total, 471 patients were given erythropoietin, and 237 patients formed the control group. The administration of erythropoietin with and without preoperative autologous blood transfusion prior to cardiac surgery is associated with a significant risk reduction: RR = 0.28 (95% CI 0.18–0.44, P < 0.001) and RR = 0.53 (95% CI 0.32–0.88, P < 0.01), respectively. Conclusion: The administration of erythropoietin before cardiac surgery is associated with a significant reduction in the risk of exposure to allogeneic blood transfusion. Further studies are warranted to define the patients' subgroups that may benefit the most from EPO administration.

[1]  K. Wilson,et al.  The cost of allogeneic red blood cells – a systematic review , 2003, Transfusion medicine.

[2]  Andrea Furlan,et al.  Updated Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review Group , 2003, Spine.

[3]  E. Crosby.  Perioperative use of erythropoietin. , 2002, American journal of therapeutics.

[4]  Karen A Robinson,et al.  Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. , 2002, International journal of epidemiology.

[5]  B. Kaya,et al.  Recombinant human erythropoietin administration in cardiac surgery. , 2001, The Journal of thoracic and cardiovascular surgery.

[6]  A. Audo,et al.  Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). , 2000, Minerva cardioangiologica.

[7]  G. Barosi,et al.  Cost‐effectiveness of epoetin and autologous blood donationin reducing allogeneic blood transfusions incoronary artery bypass graft surgery , 2000, Transfusion.

[8]  T. Yamada,et al.  Autologous blood donation with recombinant human erythropoietin in anemic patients. , 1999, The Annals of thoracic surgery.

[9]  Laupacis,et al.  Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials , 1998, Transfusion medicine.

[10]  D. Messinger,et al.  The estimation of efficacy of oral iron supplementation during treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing cardiac surgery , 1998, European journal of haematology.

[11]  S. Body,et al.  Variability in Transfusion Practice for Coronary Artery Bypass Surgery Persists Despite National Consensus Guidelines: A 24‐Institution Study , 1998 .

[12]  S. Ziemer,et al.  Evaluation of Erythropoietic Activity on the Basis of the Red Cell and Reticulocyte Distribution Widths during Epoetin Beta Therapy in Patients Undergoing Cardiac Surgery , 1998, Acta Haematologica.

[13]  James W. Jones,et al.  Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. , 1997, The Annals of thoracic surgery.

[14]  H. Warnke,et al.  Kinetics of reticulocyte maturity fractions and indices and iron status during therapy with epoetin beta (recombinant human erythropoietin) in cardiac surgery patients , 1997, American journal of hematology.

[15]  S. Ziemer,et al.  The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. , 1997, The Journal of laboratory and clinical medicine.

[16]  S. Kleinman,et al.  The Risk of Transfusion-Transmitted Viral Infections , 1996 .

[17]  H. Gombotz.  Subcutaneous epoetin alfa as an adjunct to autologous blood donation before elective coronary artery bypass graft surgery. , 1996, Seminars in hematology.

[18]  Barón Jf.  Autologous blood donation with recombinant human erythropoietin in cardiac surgery: the Japanese experience. , 1996 .

[19]  K. Messmer.  Consensus statement: using epoetin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting. Roundtable of Experts in Surgery Blood Management. , 1996, Seminars in hematology.

[20]  A. Haeberli,et al.  Use of epoetin alfa in autologous blood donation programs for patients scheduled for elective cardiac surgery. , 1996, Seminars in hematology.

[21]  J. Spivak,et al.  Clinical use of erythropoietin , 1995, Current opinion in hematology.

[22]  K. Kumon,et al.  Subcutaneous administration of recombinant human erythropoietin before cardiac surgery: a double‐blind, multicenter trial in Japan , 1994, Transfusion.

[23]  B. Reichart,et al.  Effects of Recombinant Human Erythropoietin on Autologous Blood Donation before Open Heart Surgery , 1993, The Thoracic and cardiovascular surgeon.

[24]  A. Laupacis,et al.  Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement , 1993, The Lancet.

[25]  S. Kyo,et al.  Effect of Human Recombinant Erythropoietin on Reduction of Homologous Blood Transfusion in Open‐Heart Surgery: A Japanese Multicenter Study , 1992, Circulation.

[26]  S. Yamamoto,et al.  Subcutaneous use of erythropoietin in heart surgery. , 1992, The Annals of thoracic surgery.

[27]  R. Weintraub,et al.  Comparison of two transfusion strategies after elective operations for myocardial revascularization. , 1992, The Journal of thoracic and cardiovascular surgery.

[28]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[29]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .

[30]  D. Messinger,et al.  Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoetin beta. , 1997, The Journal of laboratory and clinical medicine.

[31]  D. Messinger,et al.  Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. , 1997, Blood.

[32]  J. Baron.  Autologous blood donation with recombinant human erythropoietin in cardiac surgery: the Japanese experience. , 1996, Seminars in hematology.

[33]  S. Kleinman,et al.  The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. , 1996, The New England journal of medicine.

[34]  A. Kulier,et al.  Subcutaneous recombinant human erythropoietin and autologous blood donation before coronary artery bypass surgery. , 1993, Anesthesia and analgesia.